Platform drug technologies like RNA, personalized medicines and bacteriophages need agility in filling operations. Cytiva's Aseptic Filling Workcells can help you bring these therapies to patients faster—both in implementation and in day-to-day operations.
Cytiva works with leading mRNA and personalized medicine companies. Leading biopharma companies using Cytiva Aseptic Filling Workcells include Adaptive Phage Therapeutics, Locus Biosciences, Moderna and Roche / Genentech.
Cytiva’s Aseptic Filling Workcells are standardized products that can be built and validated in a year or less. The time saved versus conventional filling technologies enables candidates to enter the clinic faster.
Standardized machines allow ‘scale out’ models of production in personalized applications like neoantigen immunotherapies or bacteriophages. Adding identical filling machines increases capacity for small batches, and avoids scale-up technology transfer time and cost.
Automating your filling process using Cytiva Workcells can support four or more personalized batches each day and a lower cost of goods through fewer operators.
Rapid startup times and short batch changeovers support your success. Filling can begin in under an hour, including set-up and decontamination, saving time for inspection and labelling processes before dosages are frozen.
The key to reducing risk in aseptic filling is to remove the human operator from the aseptic process. Cytiva’s closed robotic workcells do not have glove ports because human intervention is designed out. We engineering the minimum possible product hazard pathway, which is limited to the inside of the single-use flow path and the dosage container.
Aseptic Filling Workcells are used for manufacturing approved commercial products. They feature robust contamination control and environmental monitoring strategies that are compliant with regulations such as Annex 1.